XiFin Receives New Growth Funding and Appoints Jeff Margolis to Board

XiFin, a leader in revenue cycle management (RCM) and billing solutions enhanced with AI, announced a new growth capital investment and the addition of Jeff Margolis to its Board of Directors. The funding round was led by a co-investment from Goldman Sachs, alongside majority investor Avista Healthcare Partners and other leading institutional investors. The investment will fuel growth and development of XiFin's award-winning Empower platform.

San Diego, CA - XiFin, a leading provider of revenue cycle management (RCM) and billing solutions enhanced with artificial intelligence (AI), has announced a significant growth capital investment and the addition of Jeff Margolis to its Board of Directors. The funding round, led by a co-investment from Goldman Sachs, alongside majority investor Avista Healthcare Partners and other leading institutional investors, will support XiFin's continued expansion and development of its award-winning XiFin® Empower platform.

The new investment follows XiFin's 19% year-over-year growth, driven by the increasing adoption of its flagship next-gen platform, XiFin® Empower, and successful execution of business opportunities. The platform unifies automation, data analytics, and AI to streamline revenue cycle workflows, improve financial performance, and enhance the patient/provider experience. XiFin® Empower connects patients, healthcare and pharmaceutical providers, and payors across the health ecosystem, extending medical providers' reach for maximum operational and clinical impact [1].

Jeff Margolis, a seasoned healthcare information technology veteran with over 35 years of experience, has joined XiFin's Board of Directors. Margolis brings extensive expertise in AI innovation and has led multiple innovative healthcare technology companies, including founding TriZetto. He currently serves as a Senior Advisor to Blackstone and board member for multiple companies, guiding strategic investments and advancing innovation in healthcare and IT. His addition to XiFin's Board will provide valuable insights and strategic guidance [1].

Erik Sallee, Chief Financial Officer at XiFin, stated, "XiFin is uniquely positioned to capitalize on an inflection point in the industry, with AI presenting a once-in-a-generation opportunity to modernize RCM. With the support of our blue-chip investors, we have excellent financial flexibility to continue solving complex healthcare challenges and delivering industry-leading technology to more partners" [1].

The new growth investments underscore a strong conviction in XiFin and the critical role its industry-leading technology plays in modernizing healthcare RCM. Marc Boheim, Head of Co-Investments at Goldman Sachs External Investing Group, said, "We believe the company has an impressive trajectory of value creation, both organically and through acquisitions, as providers turn to trusted platforms like XiFin Empower RCM to help navigate the care delivery life cycle" [1].

XiFin is supporting America's healthcare providers with solutions that unite a disconnected ecosystem, redefine RCM, and maintain focus on patient care. With the addition of Margolis and the new funding, XiFin is well-positioned to continue its growth trajectory and drive innovation in healthcare technology.

References:
[1] https://www.nasdaq.com/press-release/xifin-accelerates-ai-driven-rcm-future-new-growth-funding-and-addition-visionary
[2] https://www.stocktitan.net/news/GS/xi-fin-accelerates-ai-driven-rcm-future-with-new-growth-funding-and-ewvgvewd0l4o.html